Marie-Lisa Eich1, Alcides Chaux2, Maria Angélica Mendoza Rodriguez3, Gunes Guner3, Diana Taheri3,4, Maria Del Carmen Rodriguez Pena1, Rajni Sharma3, Mohamad E Allaf5, George J Netto1. 1. Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA. 2. Department of Scientific Research, School of Postgraduate Studies, Norte University, Asunción, Paraguay. 3. Department of Pathology, Johns Hopkins University, Baltimore, MD, USA. 4. Department of Pathology, Isfahan Kidney Disease Research Center, Isfahan University of Medical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran. 5. Department of Urology, Johns Hopkins University, Baltimore, MD, USA.
Abstract
AIMS: Among renal cell carcinoma (RCC) the tumour immune microenvironment has been best characterised in clear cell RCC. In this study we investigated the expression of several immune markers, including PD-L1, FoxP3 and CD8 in primary and metastatic papillary RCC. METHODS AND RESULTS: Three tissue microarrays were constructed from 78 cases with primary papillary RCC and paired metastatic tumour (24 cases) from 78 patients treated between 1982 and 2014. Immunohistochemistry analysis was performed using commercially available antibodies for PD-L1 (clone E1L3N), FoxP3, CD8 and Ki-67. Markers expression level in tumour and/or associated immune cells was analysed by tissue type (non-tumour versus primary tumour versus metastatic tumour) and correlated to clinicopathological features and outcome. CONCLUSION: We found PD-L1 expression in up to one-quarter of primary and metastatic papillary RCC. On univariate analysis, CD8/FoxP3 ratio >1 was associated with favourable outcome, whereas papillary RCCs with high numbers of dual CD8/Ki-67-positive lymphocytes showed an increased likelihood for tumour progression and overall and cancer-related mortality. The association of CD8/FoxP3 ratio >1 and high count of CD8/Ki-67 with outcome remained significant on multivariate analysis when adjusting for stage, grade and patient's age.
AIMS: Among renal cell carcinoma (RCC) the tumour immune microenvironment has been best characterised in clear cell RCC. In this study we investigated the expression of several immune markers, including PD-L1, FoxP3 and CD8 in primary and metastatic papillary RCC. METHODS AND RESULTS: Three tissue microarrays were constructed from 78 cases with primary papillary RCC and paired metastatic tumour (24 cases) from 78 patients treated between 1982 and 2014. Immunohistochemistry analysis was performed using commercially available antibodies for PD-L1 (clone E1L3N), FoxP3, CD8 and Ki-67. Markers expression level in tumour and/or associated immune cells was analysed by tissue type (non-tumour versus primary tumour versus metastatic tumour) and correlated to clinicopathological features and outcome. CONCLUSION: We found PD-L1 expression in up to one-quarter of primary and metastatic papillary RCC. On univariate analysis, CD8/FoxP3 ratio >1 was associated with favourable outcome, whereas papillary RCCs with high numbers of dual CD8/Ki-67-positive lymphocytes showed an increased likelihood for tumour progression and overall and cancer-related mortality. The association of CD8/FoxP3 ratio >1 and high count of CD8/Ki-67 with outcome remained significant on multivariate analysis when adjusting for stage, grade and patient's age.
Authors: Niclas C Blessin; Wenchao Li; Tim Mandelkow; Hannah L Jansen; Cheng Yang; Jonas B Raedler; Ronald Simon; Franziska Büscheck; David Dum; Andreas M Luebke; Andrea Hinsch; Katharina Möller; Anne Menz; Christian Bernreuther; Patrick Lebok; Till Clauditz; Guido Sauter; Andreas Marx; Ria Uhlig; Waldemar Wilczak; Sarah Minner; Till Krech; Christoph Fraune; Doris Höflmayer; Eike Burandt; Stefan Steurer Journal: Cell Oncol (Dordr) Date: 2021-04-17 Impact factor: 6.730
Authors: Katharina Möller; Christoph Fraune; Niclas C Blessin; Maximilian Lennartz; Martina Kluth; Claudia Hube-Magg; Linnea Lindhorst; Roland Dahlem; Margit Fisch; Till Eichenauer; Silke Riechardt; Ronald Simon; Guido Sauter; Franziska Büscheck; Wolfgang Höppner; Cord Matthies; Ousman Doh; Till Krech; Andreas H Marx; Henrik Zecha; Michael Rink; Stefan Steurer; Till S Clauditz Journal: Int Urol Nephrol Date: 2021-04-01 Impact factor: 2.370